A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs. Standard of Care as defined by the guidelines but also constrained by current drug availabilities in the different participating countries.
date de réalisation
nombre de patients
nombre de centres participants
International multicentric trial
type de financement
Private (Fonds de Dotation ACTION) & Amgen)
EUDRACT : 2021-000573-80
A study conducted by Fonds de Dotation ACTION.
Find out details and results on the dedicated page